Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GL-2045 Subcutaneous Injection in Immune Thrombocytopenia
NCT07605845Phase 1Recruiting
- Sponsor
- Gliknik
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of GL-2045 in immune thrombocytopenia (ITP) (2 cohorts), sponsored by Gliknik. Primary endpoints: Incidence, severity and type of adverse events and laboratory abnormalities and Multiple measurements of change from baseline in platelet count. Started Apr 2026; status: recruiting.
02
Drugs
GL-2045
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07605845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07605845.